SCHEMBL5579984

SCHEMBL5579984

Oc1ccc(-c2nc3cc(O)ccc3[nH]2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.59
PRKD3 O94806 1/20 0.59
PAK4 O96013 1/20 0.59
PDGFRA P16234 1/20 0.59
LTK P29376 1/20 0.59
MAP2K2 P36507 1/20 0.59
MAPK8 P45983 1/20 0.59
CDK8 P49336 1/20 0.59
RPS6KA3 P51812 1/20 0.59
PRKX P51817 1/20 0.59
NEK2 P51955 1/20 0.59
LIMK1 P53667 1/20 0.59
CDK5 Q00535 1/20 0.59
PRKCQ Q04759 1/20 0.59
MAP4K2 Q12851 1/20 0.59
ROCK1 Q13464 1/20 0.59
LRRK2 Q5S007 1/20 0.59
TAOK1 Q7L7X3 1/20 0.59
AURKB Q96GD4 1/20 0.59
CLK4 Q9HAZ1 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL415254 0.93 CHEK1 (0.55) CHEK1PRKD3PAK4PDGFRALTK
SCHEMBL2324234 0.89 NPC1 (0.62) CHEK1PRKD3PAK4PDGFRALTK
SCHEMBL14601535 0.88 AMY1A (0.51) CHEK1PRKD3PAK4PDGFRALTK
SCHEMBL27236921 0.86 MMP2 (0.55) CHEK1PRKD3PAK4PDGFRALTK
SCHEMBL31289511 0.86 MEN1 (0.63) CHEK1PRKD3PAK4PDGFRALTK
SCHEMBL7388566 0.86 GUSB (0.57) CHEK1PRKD3PAK4PDGFRALTK
SCHEMBL7394693 0.86 KDM4E (0.54) CHEK1PRKD3PAK4PDGFRALTK
SCHEMBL27873811 0.86 MEN1 (0.63) CHEK1PRKD3PAK4PDGFRALTK
SCHEMBL1665158 0.86 KDM4E (0.65) CHEK1PRKD3PAK4PDGFRALTK
SCHEMBL21705377 0.86 HDAC6 (0.64) CHEK1PRKD3PAK4PDGFRALTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070004713-A1 Therapeutic benimidazole compounds ASTRAZENECA AB (SE) 2007-01-04 US disclosed
EP-1341768-A1 THERAPEUTIC BENZIMIDAZOLE COMPOUNDS AstraZeneca AB (SE) 2003-09-10 EP disclosed
WO-2002046168-A1 THERAPEUTIC BENZIMIDAZOLE COMPOUNDS ASTRAZENECA AB (SE) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004713-A1 Therapeutic benimidazole compounds ESR2, ESRRA, ESRRB CHEK1 4381/4885PRKD3 2043/4885PAK4 4357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.